Harvard Business School has announced the 2023-2024 cohort of Blavatnik Fellows. Celebrating its 10th anniversary, the Blavatnik Fellowship in Life Science Entrepreneurship was launched in 2013 as part of a gift to Harvard University from the Blavatnik Family Foundation. The fellowship offers HBS alumni and Harvard-affiliated postdocs the opportunity to work closely with leading biotech industry and biomedical authorities, receive mentorship, and join a community of entrepreneurs shaping the future of science.
To date, Blavatnik Fellows have created 35 companies in biomedical industries, including: a novel enzymatic RNA synthesis platform, an immune system-driven dendritic cell therapy to combat cancer, new molecular technologies for the delivery of transdermal formulations, a lipid-targeting drug to treat cancer and neurodegenerative disorders, and a tumor oxygen sensor for personalized oncology care. They have collectively raised more than $500 million in funding and an additional $244 million from an IPO in June 2020. The fellowship is guided by Peter Barrett, executive fellow, and a Key Advisory Board of 13 seasoned business and biotechnology leaders who serve as one-on-one mentors and provide strategic direction during the fellows’ program year.
“This cohort of fellows bring a rich, diverse background of academic and professional experiences,” said Barrett. “From postdoctoral researchers, to science and technology policy experts, to joint degree M.B.A.s, I am certain that these fellows will be a part of the next decade of life science venture creation. I am truly delighted to continue to be a part of the fellowship’s growth and to be able to mentor the next generation of entrepreneurs who are commercializing groundbreaking technology and biomedical innovation.”